Gentherapie

Genbearbeitungstechnologien, insbesondere CRISPR/Cas9, have revolutionized the field of hematologic malignancies. By engineering CAR-T cells with CRISPR/Cas9, researchers have developed innovative therapies that enhance the specificity, potency, and durability of antitumor responses. This article analyzes the latest advancements in CRISPR/Cas9 CAR-T cell engineering, exploring the potential for improved patient outcomes and novel treatment strategies.

CRISPR/Cas9 gene editing technology offers promising avenues for restoring neurological function in conditions like ataxia. This article analyzes the potential of CRISPR/Cas9 to target genetic defects, modulate gene expression, and repair damaged neural circuits, providing insights into the potential for personalized and targeted therapies.